Everett Harris & Co. CA Invests $899,000 in CVS Health Corporation $CVS

Everett Harris & Co. CA purchased a new stake in CVS Health Corporation (NYSE:CVS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 8,693 shares of the pharmacy operator’s stock, valued at approximately $899,000.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of CVS Health by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after acquiring an additional 1,824,424 shares in the last quarter. State Street Corp grew its position in shares of CVS Health by 2.1% in the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock valued at $4,776,182,000 after purchasing an additional 1,245,457 shares during the period. Capital International Investors increased its stake in CVS Health by 3.4% during the 4th quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock worth $2,189,793,000 after purchasing an additional 900,153 shares in the last quarter. Norges Bank acquired a new stake in CVS Health during the 4th quarter worth approximately $1,666,265,000. Finally, Morgan Stanley raised its holdings in CVS Health by 6.3% during the 4th quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock worth $1,616,863,000 after buying an additional 1,211,631 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

NYSE CVS opened at $97.09 on Friday. The firm’s 50 day moving average is $102.52 and its 200-day moving average is $88.23. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $124.18 billion, a PE ratio of 25.69, a price-to-earnings-growth ratio of 0.91 and a beta of 0.61. CVS Health Corporation has a 12-month low of $67.42 and a 12-month high of $110.68.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping the consensus estimate of $1.87 by $0.71. The business had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm’s revenue was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities research analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Thursday, July 23rd. CVS Health’s dividend payout ratio is currently 70.37%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Barclays upped their price target on shares of CVS Health from $106.00 to $108.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Cantor Fitzgerald boosted their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. Weiss Ratings raised shares of CVS Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Morgan Stanley increased their target price on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Finally, Piper Sandler reissued an “overweight” rating and issued a $113.00 price target on shares of CVS Health in a research note on Monday, June 1st. Twenty-two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $106.75.

Insider Buying and Selling at CVS Health

In other news, Director Larry Robbins sold 1,983,538 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares in the company, valued at $586,842,501.45. This trade represents a 24.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders sold 3,372,000 shares of company stock valued at $317,473,598. 0.85% of the stock is owned by company insiders.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.